You are here: Industry Insights > FDA

News List

US FDA approves Neurocrine’s Ingrezza capsules to treat tardive dyskinesia pharmaceutical-technology
April 14, 2017
The US Food and Drug Administration (FDA) has approved Neurocrine Biosciences’ Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia (TD).
Analysis of New Drug Approval of FDA in 2017 Q1: Drugs Approved in the 3 Months were Nearly Half of en-cphi.cn
April 14, 2017
2017 is a year worth expecting, with the innovative drug development nonstop.
FDA approves first drug to treat tardive dyskinesia europeanpharmaceuticalreview
April 14, 2017
The US Food and Drug Administration (FDA) has approved Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia. This is the first drug approved by the FDA for this condition.
FDA Approves Ingrezza drugs.com
April 12, 2017
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved Ingrezza (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD).
FDA Grants Nanobiosym Diagnostics Emergency Use Authorization for Gene-RADAR® Zika Virus Test americanpharmaceuticalreview
April 12, 2017
Nanobiosym Diagnostics Inc. has announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the Gene-RADAR® Zika Virus Test.
Lupin receives FDA approval for generic Wellbutrin XL tabs financialexpress
April 11, 2017
The filing was done from Lupin’s Goa manufacturing facility and it will available in 150 mg and 300 mg capsules
RedHill Biopharma’s Yeliva obtains orphan drug designation from US FDA pharmaceutical-technology
April 10, 2017
RedHill Biopharma’s Yeliva (ABC294640) has secured orphan drug designation from the US Food and Drug Administration...
Supernus’ sNDAs receive final FDA approval for Trokendi XR for migraine prophylaxis pharmaceutical-technology
April 10, 2017
Supernus Pharmaceuticals has received the final approval from the US Food and Drug Administration (FDA) for its supplemental new ...
Merck receives CRL from the FDA for TECOS study with sitagliptin cphi-online
April 10, 2017
CRL relates to Merck's sNDA for Januvia, Janumet and Janumet XR.
FDA Commissioners Oppose Drug Importation lilly
April 10, 2017
Over the past few weeks, we’ve seen a variety of stakeholders raise concerns over drug importation legislation. Now, the leaders once responsible for the safety of our U.S. drug supply chain—FDA commissioners—are warning Congress of its life-threatening r

Previous page 1 2 3 4 5 6 7 8 9 10 ... 366 367 Next page